Navigation Links
Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Date:5/28/2012

NEW YORK, May 28, 2012 /PRNewswire-iReach/ -- Clinilabs, an early phase and specialty CRO that provides clinical drug development services to the pharmaceutical industry, today announced that they have opened a second Phase I unit in Southern New Jersey.  The 50-bed capacity, 15,000 square foot Specialty Pharma Phase I Unit features semi private rooms, a large PK sampling facility, a bioanalytic laboratory, pharmacy, and exam rooms.

Since 2001, Clinilabs has successfully completed clinical trials involving healthy, adult human volunteers and specialty patient populations.  The staff has accrued experience in over 800 clinical studies, offering clients the service capacity of a big CRO – delivered by an organization that is right-sized and priced for early phase projects.  The opening of the New Jersey Specialty Pharma Phase I Unit expands services currently offered at the company's 50 bed, state-of-the-art, Phase I unit in Manhattan, raising total bed capacity to 100.

"I am pleased to announce the opening of our new unit in Eatontown, New Jersey", states Dr. Gary Zammit.  "This unit allows us to expand our Phase I capacity in two locations, providing first-in-human through end-of-phase II CRO services to our clients.  We are now able to enroll larger samples of normal healthy volunteers and patient populations at our two units and at investigator sites worldwide."

About Clinilabs Inc.

Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, please visit www.clinilabs.com.

Media Contact: Hannah DAoust Clinilabs, 646-215-6480, hdaoust@clinilabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 


'/>"/>
SOURCE Clinilabs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
4. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
5. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
6. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
7. Medpace Opens Clinical Pharmacology Unit in Cincinnati, Ohio
8. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
9. EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations
10. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
11. CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... 2016 The Biotechnology industry might ... present great opportunities to investors. Stock-Callers.com assesses the recent ... (NYSE: XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... receive your complimentary trade alerts at: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):